Prospective silent-trial validation of a fine-tuned pathology foundation model for EGFR mutation screening in lung adenocarcinoma
A fine-tuned Prov-GigaPath ViT-g model, named EAGLE, predicted EGFR mutation status from routine H&E slides plus clinical features in lung adenocarcinoma. Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts. In a four-month prospective silent trial on 197 primary lung-adenocarcinoma samples, EAGLE achieved AUC 0.890. Simulated AI-assisted triage thresholds reduced rapid molecular EGFR tests by up to 43% while maintaining the study’s performance criteria.
Technology: EAGLE, a task-specific model fine-tuned from the Prov-GigaPath ViT-g pathology foundation model, combining H&E whole-slide image features with clinical variables for EGFR mutation prediction
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts.
- Still unknown: The four-month prospective trial was silent: AI outputs did not guide care or replace standard testing. The 43% reduction is a simulated triage workflow at a selected score threshold, not an observed reduction in tests or evidence of improved outcomes. The cohort was 197 primary cases at one real-time deployment site, while broader retrospective/external cohorts supported generalization. EAGLE predicts presence of EGFR mutation but does not identify the mutation subtype; sequencing remains necessary before treatment. Performance was lower on metastatic samples. The paper is a distinct 2025 model iteration and validation study in the lineage of the group’s 2022 arXiv proof of concept (10.48550/arXiv.2206.10573); the prior work is cited as antecedent, not treated as a second alias or hidden as the first-ever pathology-image EGFR result.
- AI role: The AI model predicted tumor EGFR mutation status directly from routine H&E digital slides, using sequencing results as ground truth. Fine-tuning the pathology foundation model produced cross-institution validation, and real-time inference in a prospective silent trial tested generalization on newly processed clinical slides. The model score was evaluated as a screening/triage layer alongside rapid molecular testing; it did not replace genomic sequencing.
Evidence sources: https://www.nature.com/articles/s41591-025-03780-x
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 106 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.